沙利度胺加VAD联合化疗治疗多发性骨髓瘤临床观察

目的评价沙利度胺加VAD（T—VAD）联合化疗对MM患者的临床疗效和不良反应。方法21例MM患者采用沙利度胺联合VAD（T—VAD）方案治疗2-4个疗程，评价其疗效和不良反应。结果20例可评价疗效的患者，7例（35％）获得CR，8例（40％）获得PR，总有效率（CR＋PR）为75％，中位生存时间为50个月。所有患者共接受66个疗程的化疗，最常见的不良反应为指端麻木感（30％），便秘（20％），嗜睡（20％），水肿（15％），未发现1例DVT。结论沙利度胺加VAD（T-VAD）联合化疗治疗多发性骨髓瘤疗效好，不良反应轻微，易于耐受。

Clinical observations of Thalidomide plus VAD(T-VAD)in treating multiple mytloma

Objective To evaluate the clinical effects and the side-effects of thalidomide plus VAD (T-VAD)united-chemotherapy in treating multiple mytloma.Methods Twenty one patients with Thalidomide plus VAD(T-VAD)were treated for 2~4 course of treatment,in order to evaluate its clinical effects and the side-effects. Results In twenty effective patients,about 7 patients(35%)gained complete response(CR),8 patients(40%)gai ned partlyresponse(PR),and the total effective rate(CR PR)is 75%,the middle survive time are 50 months. All the patients received 66 course of treatments,the common side-effects were the numb of fingers (30%),constipation (20%),edema(15%),butthe deep vein thrombus(DVT)is not found.Conclusion Thalidomide plus VAD(T-VAD) united-chemotherapytreated for multiple mythloma gets well effects,seldomside-effects,and be easytoendure.